Capital International Investors Ultragenyx Pharmaceutical Inc. Transaction History

Capital International Investors

$504 Billion
Q3 2024

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 11, 2023	SELL	$37.35 - $52.15 $12.2 Million - $17.1 Million	-327,203 Reduced 25.28%	967,357 $44.6 Million
Q4 2022 Feb 14, 2023	SELL	$33.72 - $46.33 $70.7 Million - $97.1 Million	-2,096,522 Reduced 61.82%	1,294,560 $60 Million
Q3 2022 Nov 14, 2022	SELL	$39.96 - $66.14 $852,107 - $1.41 Million	-21,324 Reduced 0.62%	3,391,082 $140 Million
Q2 2022 Aug 15, 2022	BUY	$45.8 - $85.4 $3.09 Million - $5.75 Million	67,380 Added 2.01%	3,412,406 $204 Million
Q1 2022 May 16, 2022	SELL	$62.2 - $84.4 $126 Million - $171 Million	-2,024,748 Reduced 37.71%	3,345,026 $243 Million
Q4 2021 Feb 14, 2022	SELL	$73.71 - $87.86 $21.8 Million - $26 Million	-295,419 Reduced 5.21%	5,369,774 $452 Million
Q3 2021 Nov 15, 2021	BUY	$77.92 - $102.4 $16.2 Million - $21.3 Million	208,069 Added 3.81%	5,665,193 $511 Million
Q2 2021 Aug 16, 2021	BUY	$92.19 - $115.71 $3.04 Million - $3.82 Million	33,002 Added 0.61%	5,457,124 $520 Million
Q1 2021 May 14, 2021	SELL	$106.9 - $167.73 $89.5 Million - $140 Million	-837,184 Reduced 13.37%	5,424,122 $618 Million
Q4 2020 Feb 12, 2021	BUY	$84.4 - $177.39 $5.35 Million - $11.2 Million	63,357 Added 1.02%	6,261,306 $867 Million
Q3 2020 Nov 13, 2020	BUY	$72.98 - $90.0 $8.23 Million - $10.2 Million	112,817 Added 1.85%	6,197,949 $509 Million
Q2 2020 Aug 14, 2020	SELL	$46.91 - $78.22 $2.21 Million - $3.68 Million	-47,062 Reduced 0.77%	6,085,132 $476 Million
Q1 2020 May 15, 2020	BUY	$33.8 - $62.9 $3.03 Million - $5.64 Million	89,619 Added 1.48%	6,132,194 $272 Million
Q4 2019 Feb 18, 2020	BUY	$36.08 - $45.83 $1.22 Million - $1.55 Million	33,818 Added 0.56%	6,042,575 $258 Million
Q3 2019 Nov 14, 2019	BUY	$42.5 - $63.11 $16.6 Million - $24.6 Million	390,195 Added 6.94%	6,008,757 $257 Million
Q2 2019 Aug 14, 2019	BUY	$54.93 - $74.36 $2.75 Million - $3.72 Million	50,013 Added 0.9%	5,618,562 $357 Million
Q1 2019 May 15, 2019	BUY	$39.87 - $69.36 $39 Million - $67.9 Million	978,695 Added 21.32%	5,568,549 $386 Million
Q4 2018 Feb 14, 2019	BUY	$38.89 - $77.3 $8.94 Million - $17.8 Million	229,963 Added 5.27%	4,589,854 $200 Million
Q3 2018 Nov 14, 2018	BUY	$71.81 - $90.15 $54.2 Million - $68.1 Million	755,127 Added 20.95%	4,359,891 $333 Million
Q2 2018 Aug 14, 2018	BUY	$48.54 - $85.31 $665,871 - $1.17 Million	13,718 Added 0.38%	3,604,764 $277 Million
Q1 2018 May 15, 2018	BUY	$44.33 - $58.52 $543,441 - $717,396	12,259 Added 0.34%	3,591,046 $183 Million
Q4 2017 Feb 14, 2018	BUY	$43.54 - $57.32 $29.8 Million - $39.2 Million	683,306 Added 23.6%	3,578,787 $166 Million
Q3 2017 Nov 14, 2017	BUY	$49.79 - $66.32 $144 Million - $192 Million	2,895,481	2,895,481 $154 Million

Others Institutions Holding RARE

# of Institutions

325

Shares Held

85.5M

Call Options Held

520K

Put Options Held

406K

Vanguard Group Inc Valley Forge, PA

9.95M
Shares

$427 Million
0.01% of portfolio
Black Rock Inc. New York, NY

5.6M
Shares

$241 Million
0.01% of portfolio
Sands Capital Management, LLC Arlington, VA

5.12M
Shares

$220 Million
0.91% of portfolio
Wellington Management Group LLP Boston, MA

4.17M
Shares

$179 Million
0.04% of portfolio
Price T Rowe Associates Inc Baltimore, MD

3.07M
Shares

$132 Million
0.02% of portfolio

View Full List

About Ultragenyx Pharmaceutical Inc.

Ticker RARE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,036,896
Market Cap $3.01B
Description
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...

More about RARE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Capital International Investors, based on Form 13F filings with the SEC.

News

Stay updated on Capital International Investors with notifications on news.

Account